Home > Business > Industry

Samsung Biologics signs 1.8 trillion won deal with U.S. pharma firm

Published: 09 Sep. 2025, 11:39

Bottles of pharmaceutical products are displayed at the Samsung Biologics promotion center in Yeonsu District, Incheon, on May 25, 2021. [YONHAP]

Samsung Biologics, Korea's leading biotech firm, said Tuesday it has secured a 1.8 trillion-won ($1.29 billion) contract to provide manufacturing services for a U.S. pharmaceutical company through 2029.

The latest agreement raises the company's cumulative contract manufacturing value this year to more than $3.6 billion, it said in a press release.

Samsung Biologics said it has landed sizable deals this year by responding to evolving client needs in Asia, Europe and the United States.

The company has partnerships with 17 of the world's top 20 pharmaceutical firms and continues to extend contracts with existing clients to support the development of new therapies, the release said.

Samsung Biologics currently operates five biopharmaceutical plants in Songdo, Incheon, with three additional facilities scheduled for completion by 2032.

Its existing plants have a combined annual capacity of 784,000 liters (207,083 gallons), which will increase to 1.324 million liters once the new facilities come online.

In the first half of this year, Samsung Biologics' operating profit jumped 47 percent on-year to 962.29 billion won on revenue of 2.59 trillion won, up 23 percent from a year earlier.

Yonhap